The BioPharm Brief: CAR-T Advances, Pediatric Biologic Approval, and Oral GLP-1 Progress

Apr 23, 06:20 PM
Headliner
Share
Subscribe

New developments in CAR-T therapy, pediatric biologics, and oral GLP-1 treatments highlight expanding innovation across oncology, immunology, and metabolic disease. Early data and regulatory progress signal a shift toward more targeted and accessible therapies for underserved patient populations.

Share
Subscribe
Next
The BioPharm Brief: Innovation, Gene Therapy Momentum, and Next-Gen ADCs Lead Today’s Headlines
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief